Related Experiment Video
Updated: Nov 22, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.5K
Modular machine learning for Alzheimer's disease classification from retinal vasculature
Jianqiao Tian1, Glenn Smith2, Han Guo3
1J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, 32611, USA.
Scientific Reports
|January 9, 2021
Summary
Researchers developed a machine learning pipeline using retinal images to screen for Alzheimer's disease (AD), a common cause of dementia. This cost-effective method achieved 82.44% accuracy, identifying small retinal vessels as key diagnostic indicators.
Area of Science:
- Ophthalmology
- Neurology
- Artificial Intelligence
Background:
- Alzheimer's disease (AD) is the primary cause of dementia, necessitating early detection for effective treatment.
- Current diagnostic imaging for AD is expensive and not widely accessible, limiting routine screening.
- The retina's vasculature presents a potential, accessible alternative for AD screening.
Purpose of the Study:
- To evaluate the feasibility of using retinal vasculature analysis for early Alzheimer's disease screening.
- To develop and validate a machine learning pipeline for detecting AD from retinal images.
Main Methods:
- A highly modular machine learning pipeline was designed for image analysis.
- Data from the UK Biobank was utilized for training and testing the pipeline.
- Saliency analysis was incorporated to enhance model interpretability.
Main Results:
- The machine learning pipeline achieved an average classification accuracy of 82.44% in identifying Alzheimer's disease.
- Saliency analysis revealed that small retinal vessels are significant indicators for AD diagnosis.
- Findings align with existing research on the link between retinal changes and neurodegenerative diseases.
Conclusions:
- Retinal vasculature analysis using machine learning is a promising, accurate, and potentially cost-effective method for Alzheimer's disease screening.
- The developed pipeline offers a novel approach to complement existing diagnostic tools.
- Further research can refine this technique for clinical application in dementia screening.
Related Concept Videos
Alzheimer's Disease: Overview
1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Alzheimer's Disease: Treatment
589
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
589

